Access Pharmaceuticals Announces MuGard License Agreement With Hanmi Pharmaceutical In Korea

     Access Pharmaceuticals Announces MuGard License Agreement With Hanmi
                           Pharmaceutical In Korea

PR Newswire

NEW YORK, March 11, 2014

ACCP) today announced that it had entered into an exclusive license agreement
with HANMI PHARMACEUTICAL CO., LTD. (KSE: 128940) related to MuGard
commercialization in South Korea. Under the terms of the license agreement,
Access will receive an upfront licensing fee and double digit royalties on net
sales of MuGard in the licensed territory. MuGard is an oral mucoadhesive that
is designed to manage oral mucositis by forming a protective hydrogel coating
over the oral mucosa to shield the membranes of the mouth and tongue. Oral
mucositis is a common side effect of cancer treatments, with approximately
400,000 patients in the US alone developing the condition each year.

"Access is pleased to announce this partnership with Hanmi Pharmaceuticals, a
leader in Korea, as we believe that international expansion and licensing is
critical to the commercial success of MuGard," said Jeffrey B. Davis,
President and CEO of Access Pharmaceuticals, Inc. "Hanmi's international
presence, resources and strategic emphasis on expansion makes them an ideal
partner for MuGard. With the recent publication of MuGard clinical data,
completion of this third marketing partnership, and active discussions with
additional partnerships abroad, Access is laying the foundation for MuGard
growth globally."

Access recently announced publication of positive MuGard clinical data in
Cancer, the journal of the American Cancer Society. The publication, entitled
"Multi-Institutional, Randomized, Double-Blind, Placebo-Controlled Trial to
Assess the Efficacy of a Mucoadhesive Hydrogel (MuGard) in Mitigating Oral
Mucositis Symptoms in Patients Being Treated With Chemoradiation Therapy for
Cancers of the Head and Neck," is available at

About Oral Mucositis: Oral mucositis ("OM") is a debilitating side effect of
some radiation and chemotherapy cancer treatments, characterized by sores and
ulcers in the mouth and throat that make swallowing difficult or impossible.
It is estimated that 97% of patients receiving radiation for head and neck
cancer, 70% of patients receiving stem cell transplantation and up to 40% of
patients receiving conventional chemotherapy develop oral mucositis. There are
an estimated 400,000 patients diagnosed with OM in the US annually, but OM is
often under-diagnosed and the population at risk is significantly higher.

About MuGard: MuGard^® Mucoadhesive Oral Wound Rinse is indicated for the
management of oral mucositis/stomatitis (that may be caused by radiotherapy
and/or chemotherapy) and all types of oral wounds (mouth sores and injuries),
including aphthous ulcers/canker sores and traumatic ulcers, such as those
caused by oral surgery or ill-fitting dentures or braces. MuGard is available
by prescription only and is contraindicated in patients with known
hypersensitivity to any of the ingredients in the formulation. MuGard was
launched in 2010 after receiving 510(k) clearance from the U.S. Food and Drug
Administration and is marketed by AMAG Pharmaceuticals, Inc. in the United

About Hanmi: Established in 1973, Hanmi Pharmaceutical dedicates over 15% of
its annual revenue into research and development on novel drug discovery and
incrementally modified drugs. Hanmi transferred its technology to Roche and
Novartis in what was Korea's first and largest scale in drug technology
export. Hanmi further raised its global profile and recognition as the
pharmaceutical leader of South Korea following its export license and
agreement with Merck on Hanmi's fixed dose hypertension drug Amosartan.
Beginning with the establishment of Beijing Hanmi Pharmaceutical Co., Ltd in
domestic China, Hanmi is expanding its global presence into major markets such
as Japan, Europe and USA. For more information, please visit

About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical
company that develops and commercializes proprietary products for the
treatment and supportive care of cancer patients. Access developed MuGard and
is developing multiple follow-on products. Access also has other advanced drug
delivery technologies including CobaCyte™-mediated targeted delivery and
CobOral-oral drug delivery, its proprietary nanopolymer delivery technology
based on the natural vitamin B12 uptake mechanism. For additional information
on Access Pharmaceuticals, please visit our website at

This press release contains certain statements that are forward-looking within
the meaning of Section 27a of the Securities Act of 1933, as amended, and that
involve risks and uncertainties. These statements include those relating to:
our cash burn rate, clinical trial plans and timeliness and clinical results
for MuGard and Cobalamin, our ability to achieve clinical and commercial
success and our ability to successfully develop marketed products. These
statements are subject to numerous risks, including but not limited to Access'
need to obtain additional financing in order to continue the clinical trial
and operations and to the risks detailed in Access' Annual Reports on Form
10-K and other reports filed by Access with the Securities and Exchange

Company and Media Contact:
Christine Berni
Access Pharmaceuticals, Inc.
(212) 786-6208

SOURCE Access Pharmaceuticals, Inc.

Press spacebar to pause and continue. Press esc to stop.